787.29
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$787.82
Offen:
$787.82
24-Stunden-Volumen:
586.24K
Relative Volume:
0.76
Marktkapitalisierung:
$97.93B
Einnahmen:
$377.60B
Nettoeinkommen (Verlust:
$3.35B
KGV:
31.41
EPS:
25.0619
Netto-Cashflow:
$5.67B
1W Leistung:
+0.69%
1M Leistung:
+12.74%
6M Leistung:
+15.36%
1J Leistung:
+54.88%
Mckesson Corporation Stock (MCK) Company Profile
Firmenname
Mckesson Corporation
Sektor
Branche
Telefon
972-446-4800
Adresse
6555 STATE HIGHWAY 161, IRVING, TX
Vergleichen Sie MCK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MCK
Mckesson Corporation
|
787.29 | 97.99B | 377.60B | 3.35B | 5.67B | 25.06 |
![]()
COR
Cencora Inc
|
328.82 | 63.47B | 316.65B | 1.91B | 1.14B | 9.7209 |
![]()
CAH
Cardinal Health Inc
|
158.68 | 37.36B | 222.58B | 1.57B | 1.85B | 6.4395 |
![]()
HSIC
Henry Schein Inc
|
64.23 | 7.75B | 12.50B | 314.00M | 421.00M | 2.44 |
![]()
AHG
Akso Health Group Adr
|
1.63 | 911.67M | 2.22M | -5.63M | -1.68M | -0.24 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-04 | Fortgesetzt | Mizuho | Neutral |
2024-11-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2024-09-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-09-05 | Bestätigt | Leerink Partners | Outperform |
2024-08-08 | Bestätigt | Mizuho | Neutral |
2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
2024-01-03 | Eingeleitet | Barclays | Overweight |
2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
2023-03-31 | Eingeleitet | Citigroup | Buy |
2022-08-22 | Fortgesetzt | Morgan Stanley | Overweight |
2022-07-06 | Herabstufung | Argus | Buy → Hold |
2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
2022-02-04 | Herabstufung | Deutsche Bank | Buy → Hold |
2022-01-07 | Hochstufung | Credit Suisse | Neutral → Outperform |
2021-11-02 | Bestätigt | Barclays | Overweight |
2021-11-02 | Bestätigt | BofA Securities | Buy |
2021-11-02 | Bestätigt | Evercore ISI | Outperform |
2021-11-02 | Bestätigt | Jefferies | Buy |
2021-03-30 | Hochstufung | Argus | Hold → Buy |
2020-11-02 | Hochstufung | Barclays | Equal Weight → Overweight |
2020-08-04 | Hochstufung | Deutsche Bank | Hold → Buy |
2020-05-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-05-15 | Hochstufung | UBS | Neutral → Buy |
2020-04-23 | Fortgesetzt | Credit Suisse | Neutral |
2020-03-18 | Hochstufung | Goldman | Neutral → Buy |
2020-03-13 | Hochstufung | Guggenheim | Neutral → Buy |
2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2020-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
2019-08-05 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2019-07-22 | Eingeleitet | Guggenheim | Neutral |
2019-01-17 | Eingeleitet | UBS | Neutral |
2018-10-26 | Bestätigt | Barclays | Equal Weight |
2018-07-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2018-05-29 | Bestätigt | Leerink Partners | Mkt Perform |
2018-03-08 | Eingeleitet | Barclays | Equal Weight |
2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
2018-02-02 | Bestätigt | Mizuho | Neutral |
2018-01-24 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Mckesson Corporation Aktie (MCK) Neueste Nachrichten
What machine learning models say about McKesson CorporationBond Market & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-21 22:18:03 - newser.com
Will McKesson Corporation benefit from macro trendsEarnings Recap Report & AI Driven Stock Price Forecasts - newser.com
Will McKesson Corporation stock beat Nasdaq index returnsChart Signals & Safe Entry Point Alerts - newser.com
Can McKesson Corporation stock withstand sector downturnsJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
McKesson appeals $152 million Baltimore opioid judgment - Baltimore Sun
Risk vs reward if holding onto McKesson CorporationJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Sector ETF performance correlation with McKesson CorporationTrade Analysis Summary & Community Verified Swing Trade Signals - newser.com
Is McKesson Corporation stock bottoming out2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Is McKesson Corporation stock a momentum leaderFed Meeting & Comprehensive Market Scan Reports - newser.com
What moving averages say about McKesson CorporationJuly 2025 Market Mood & AI Driven Stock Price Forecasts - newser.com
What MACD trends signal for McKesson Corporation (MCK) stockTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
Chart overlay techniques for tracking McKesson CorporationMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Tools to monitor McKesson Corporation recovery probabilityEarnings Miss & AI Driven Stock Price Forecasts - newser.com
Why McKesson Corporation stock remains stableJuly 2025 Highlights & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of McKesson Corporation with statistical toolsJuly 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
Why McKesson Corporation (MCK) stock stays on buy listsPortfolio Risk Summary & High Conviction Buy Zone Alerts - nchmf.gov.vn
Will McKesson Corporation stock gain from green policies2025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Citius Oncology adds McKesson as distributor for lymphoma therapy - Investing.com
Citius Oncology signs U.S. distribution agreement with McKesson to support Lymphir commercial launch - MarketScreener
Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch - TradingView
Can McKesson Corporation stock maintain growth trajectory2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch - Stock Titan
Chart based exit strategy for McKesson Corporation2025 Price Momentum & Low Risk Entry Point Guides - newser.com
McKesson Corporation (MCK) Stock Analysis: Unveiling Growth Potential with a 6.45% Upside - DirectorsTalk Interviews
Relative strength of McKesson Corporation in sector analysis2025 Price Targets & Weekly High Momentum Picks - newser.com
Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Support & Resistance & Verified Short-Term Trading Plans - newser.com
McKesson Corporation stock daily chart insightsJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory - Yahoo Finance
Can McKesson Corporation stock continue upward trendJuly 2025 Update & Verified Entry Point Signals - nchmf.gov.vn
Buybacks Report: Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Pullback Review & Consistent Income Trade Recommendations - nchmf.gov.vn
How McKesson Corporation stock benefits from tech adoption2025 Biggest Moves & High Accuracy Trade Alerts - nchmf.gov.vn
McKesson (MCK): Evaluating Valuation After Launching PHYRAGO Oncology Partnership - simplywall.st
Portfolio Update: Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Earnings Impact & Fast Moving Market Watchlists - nchmf.gov.vn
Finanzdaten der Mckesson Corporation-Aktie (MCK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):